Ludwig, H. Et Al. 2023. Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network. The Lancet Oncology , vol.24, no.6 .

Ludwig, H., Terpos, E., van de Donk, N., Mateos, M., Moreau, P., Dimopoulos, M., ... Delforge, M.(2023). Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network. The Lancet Oncology , vol.24, no.6.

Ludwig, Heinz Et Al. "Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network," The Lancet Oncology , vol.24, no.6, 2023

Ludwig, Heinz Et Al. "Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network." The Lancet Oncology , vol.24, no.6, 2023

Ludwig, H. Et Al. (2023) . "Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network." The Lancet Oncology , vol.24, no.6.

@article{article, author={Heinz Ludwig Et Al. }, title={Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network}, journal={The Lancet Oncology}, year=2023}